Teva signs $125m deal with Royalty Pharma on antipsychotic drug
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Royalty Pharma plc (Nasdaq: RPRX), announced today a collaboration to accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749)…